Pages

Sunday, January 27, 2013

Snoring Can Affect The Carotid Artery

People who snore regularly have a much higher risk of having thicker or abnormal carotid arteries, researchers from the Henry Ford Hospital, Detroit, reported. They added that the risk is greater for snorers than overweight people and smokers.

When the lining of the two blood vessels that nourish the brain with oxygen-rich blood thicken, it is usually the first step towards the development of atherosclerosis(hardening of the arteries), the researchers explained. Atherosclerosis causes several vascular diseases.

The left and right common carotid arteries supply the head and neck with oxygenated blood - they divide the neck to form the external and internal carotid arteries.

Lead study author Robert Deeb, M.D., said:

"Snoring is more than a bedtime annoyance and it shouldn't be ignored. Patients need to seek treatment in the same way they would if they had sleep apnea, high blood pressure or other risk factors for cardiovascular disease.

Our study adds to the growing body of evidence suggesting that isolated snoring may not be as benign as first suspected. So instead of kicking your snoring bed partner out of the room or spending sleepless nights elbowing him or her, seek out medical treatment for the snorer."


The researchers found that snorers, including those with no sleep apnea, had alterations in the carotid artery. They believe the changes are most likely caused by trauma and subsequentinflammation that the snoring vibrations cause.

The scientists presented their findings at the 2013 Combined Sections Meeting of the Triological Society in Scottsdale, Arizona. They also submitted their research to The Laryngoscope for publication.

Research findings on snoring have been contradictory

In October 2012, researchers from the Woolcock Institute of Medical Research, Australia, found that snoring is not a risk factor for cardiovascular disease or mortality, regardless of whether or not the person has sleep apnea. They added that those who snore every night are not more likely to die within the next seventeen years than relatively infrequent snorers.

Hungarian researchers in 2008 reported in the journal Sleep that loud snorers are considerably more likely to develop stroke and heart disease compared to those who never or very rarely snore. Their study, involving 12,643 Hungarian adults, found that about 40% of males and 24% of females snore regularly.

Snoring causes cardiovascular disease, long before OSA does

OSA (obstructive sleep apnea) has been linked to the development of cardiovascular disease, as well as some other illnesses.

The scientists believe that for cardiovascular disease, the problem probably starts with snoring, long before OSA sets in. So far, very few studies have demonstrated an association between snoring and cardiovascular disease risk.

Dr. Deeb along with senior study author Kathleen Yaremchuk, M.D. gathered and examined data on 913 patients who had been evaluated by the Henry Ford Hospital's sleep center. The patients had taken part in a diagnostic sleep study from December 2006 to January 2012. They were aged from 18 to 50 years; none of them had sleep apnea at baseline.

Fifty-four of the patients completed the snore outcomes survey which examined their snoring habits. They had also undergone a carotid artery duplex ultrasound to determine how thick the intima-media of their carotid arteries were.

Carotid intima-media thickness is a measurement of the two innermost layers of the arterial wall, and can be used to determine whether there is any atherosclerotic disease. If the intima-media is too thick, it is usually an initial sign of carotid artery disease.
 The researchers found that snorers have considerably thicker intima-media of the carotid arteries compared to people who do not snore.

There was no considerable difference in intima-media thickness between patients with traditional cardiovascular disease risk factors and those without. Risk factors for cardiovascular disease include high blood pressure (hypertension), high blood cholesterol(hypercholesterolemia), smoking and diabetes.

Dr. Deeb said:

"Snoring is generally regarded as a cosmetic issue by health insurance, requiring significant out-of-pocket expenses by patients. We're hoping to change that thinking so patients can get the early treatment they need, before more serious health issues arise."


The team plan to carry out another long term study on people who snore during their sleep. They say they will focus on whether there is a link between cardiovascular event rates and snoring.

The study was funded by the Henry Ford Hospital.

What are the causes of snoring?

Snoring occurs when the soft tissue at the back of a person's head and neck vibrates as they breathe in.

The following tissue may be affected:
  • the nasal passages
  • the soft palate - the soft tissue at the back of the roof of the mouth
  • the base of the tongue
  • the tonsils
  • the uvula - a soft section of tissue that hangs from the soft palate between a person's tonsils
When we sleep, the airways in our head and neck relax and gradually narrow. Experts explain that this airways narrowing raises the speed at which air is breathed in and out, causing changes in pressure inside, making the soft tissue vibrate as the sides of the airways are sucked inwards.

The same can occur when the airways are partially blocked, as may be the case with enlarged tonsils or when somebody has a cold.

Doctors say that snoring typically gets worse over time if it is not treated. The muscles gradually get weaker, making it harder to keep the airways open, resulting in even more frequent and louder snoring.

The following situations, illnesses and conditions are linked to a higher risk of habitual snoring:
  • Being obese - especially if there is a lot of fat around the person's neck.
  • Alcohol - when we drink alcohol our muscles relax
  • Some antidepressants and sedatives - some of these drugs relax the muscles, raising the risk of snoring
  • Tobacco smoking - the airways are more likely to become inflamed, making them narrower, resulting in snoring
  • Allergic rhinitis - when the inside of the nose swells up because of an allergic reaction. Dust or pollen (hay fever) are common examples of allergic rhinitis
Written by Christian Nordqvist
Copyright: Medical News Today 

Three Type 2 Diabetes Pills From Takeda Approved By FDA

Nesina (alogliptin) tablets, Oseni (alogliptin and pioglitazone) tablets, and Kazano (alogliptin and metformin hydrochloride) tablets, for the treatment of type 2 diabetes, for use along with diet and exercise, have been approved by the Food and Drug Administration. They are designed to improve blood sugar control.

The active ingredients pioglitazone and metformin hydrochloride are already approved by the FDA for type 2 diabetesmanagement - Alogliptin is new.

According to the FDA in a communiqué issued on January 25th, 2013, 24 million Americans live with type 2 diabetes, which accounts for over 90% of all diabetes cases in the country.

Patients with type 2 diabetes either do not produce enough insulin, or are resistant to it - in both cases their blood sugar levels are too elevated. Eventually, high blood sugar levels can lead to serious and life-threatening complications, such as kidney damage, blindness and heart disease.

Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said:

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes. Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."


Nesina, Oseni and Kazano were studied as monotherapies and also in combination with insulin and sulfonylureas. A monotherapy is a stand-alone therapy, one that is not given in combination with another drug.

These therapies should not be prescribed for patients with type 1 diabetes or people with diabetic ketoacidosis (high ketone urine levels).

Nesina (alogliptin) tablets

Nesina is a DPP-4i (dipeptidyl peptidase-4 inhibitor). It is designed to slow down the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).

Nesina (alogliptin) was shown to be both effective and safe in 14 human studies, which included 8,500 participants; all of them with type 2 diabetes:
  • Patients on Nesina had reductions in HbA1c (glycosylated hemoglobin) of 0.4% to 0.6% compared to those on placebo after 26 weeks on the medication

  • The FDA says it needs five post-marketing Nesina studies: "a cardiovascular outcomes trial; an enhanced pharmacovigilance program to monitor for liver abnormalities, serious cases of pancreatitis, and severe hypersensitivity reactions; and three pediatric studies under the Pediatric Research Equity Act (PREA), including a dose finding study and two safety and efficacy studies, one with Nesina as a monotherapy and one with Nesina and metformin."

  • Nesina's most commonly reported side effects included upper respiratory tract infection,headache, and runny nose.
  • Kazano (alogliptin and metformin hydrochloride) tablets

    Kazano is a combination of alogliptin and metformin HCl, a extensively used anti-diabetes medication, in a single tablet.
  • Kazano was shown to be both safe and effective in four clinical trials, which included over 2,500 participants, all of them with type 2 diabetes:
    • Those on Kazano had additional reductions in HbA1c of 1.1% over Nesina, and 0.5% over metformin after being on therapy for 26 weeks

    • The FDA says it needs two post-marketing Kazano studies: a pediatric efficacy and safety study under PREA, and an enhanced pharmacovigilance program to check for liver abnormalities, pancreatitis, and severe hypersensitivity reactions

    • It carries a Boxed Warning regarding lactic acidosis (accumulation of lactic acid in the bloodstream), which is linked to metformin use

    • The most commonly reported side effects related to Kazano were stuffy/runny nose, sore throat, headache, hypertensiondiarrheaback painurinary tract infection, and upper respiratory tract infection.

    Oseni (alogliptin and pioglitazone) tablets

    Oseni, a combination of alogliptin and pioglitazone, is the first medication in the USA to include both a DPP-4i and a TZD (thiazolidinedione) in a single tablet.

    Oseni was shown to be both safe and effective in four clinical trials which included over 1,500 participants, all of them with type 2 diabetes:
    • The patients on Oseni had additional reductions in HbA1c of 0.4% to 0.6% over pioglitazone alone, and 0.4% to 0.9% over alogliptin alone

    • The FDA says it needs an enhanced pharmacovigilance program for Oseni to check for abnormalities of the liver, pancreatitis, and severe hypersensitivity reactions

    • There is a Boxed Warning in the Oseni packaging, warning about heart failure linked to pioglitazone use

    • The most commonly reported side effects related to Oseni are sore throat, runny nose, upper respiratory infection, and back pain.
    Oseni, Kazano and Nesina are made and distributed by Takeda Pharmaceuticals America, Inc., Deerfield, Illinois, USA.

    Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc., said:

    "Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience. Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."


    According to Takeda, type 2 diabetes is a "progressive and chronic (long-term) condition." Patients should work with a doctor to manage and monitor their disease. As well as adhering to a diet and exercise program, patients need to take several drugs in order to help them manage their blood glucose levels.

    Currently, approximately $471.6 billion are spent annually worldwide on diabetes (both types 1 and 2). The International Diabetes Federation estimates that this yearly expenditure will rise to over $595 billion within the next 17 years.

    Written by Joseph Nordqvist 
  • Copyright: Medical News Today 

CBSE launches assessment training programme

KOCHI: Central Board of Secondary Education's Centre for Assessment, Evaluation & Research (CAER) has launched an assessment trainingprogramme. 

CBSE had established CAER through public private partnership with Pearson Foundation. 

The purpose of the Centre is to develop global capabilities and resources for schools, teachers and key functionaries of school management. 

It is envisaged through this endeavour that a symbiosis of the expertise and experience of the board and the partner organization, Pearson Foundation, will help in bringing about an overall improvement in the quality of learning, assessment, research and professional development. 

It is important for all the stakeholders in the CBSE affiliated schools to know that the Centre which has taken strides to formulate the first of a series of professional development programmes for teachers and principals will roll out its Assessment Training Programme (ATP) in February 2013. 

The ATP comprises four modules — constructing quality multiple choice items to assess the scholastic skills of the curriculum, constructing quality constructed-response items to assess the scholastic skills of the curriculum, formative assessment and the use of performance standards for assessing scholastic and co-scholastic skills and classroom-based research. 

"Participation in all four modules and the fulfilment of the required follow up activity will allow those attending to submit evidence for a qualification. Whether or not delegates opt for the qualification, successful participation will create a pool of assessment experts in the country as well as build assessment capacity of teachers in India. All CBSE schools may consider participating whole heartedly in the aforesaid programme", CBSE circular to schools state. 
Source:The Times Of India

Sikkim Manipal Institute of Technology Invites Applications for Medical Programs


Applications are invited by Sikkim Manipal Institute of Technology (SMIT), Rangpo for admission to four and half year Bachelor of Medicine and Bachelor of Surgery (MBBS), three years Bachelor in Medical Lab Technology (BMLT), three years Master of Science (M.Sc) in Anatomy, Physiology, Biochemistry & Microbiology offered atSikkim Manipal Institute of Technologyand two year Mater of Physiotherapy (MPT) programs offered at Sikkim Manipal College of Physiotherapy for the session 2013.
Eligibility Criteria for SMIT, Rangpo
  • For MBBS Program:
    • All candidates must be 17 years if age or older as December 31, 2103.
    • Candidates must have passed in the subjects of Physics, Chemistry, Biology/Bio-technology and English individually and must have obtained a minimum of 50% marks taken together in Physics, Chemistry and Biology/Bio-Technology at the qualifying examination(10+2 or equivalent).
  • For BMLT Program:
    • Candidates must have passed (10+2) or equivalent examination with Physics, Chemistry, Biology/Bio-Technology with minimum of 50% aggregate marks (45% marks for SC/ST/OBC category)
  • For M.Sc (Medical) Programs:
    • Candidates must have passed 3-years B.Sc course in any branch of Life Science i.e Physiology, Zoology, Botany, Microbiology and Chemistry.
  • For MPT Program:
    • Candidates must have passed in bachelor of Physiotherapy examination from full-time, in campus BPT course program from an institution/university duly recognized by the Indian Association of Physiotherapist.
For more details and information on eligibility criteria, please visit their official website.
How to Apply for SMIT, Rangpo
  • Candidates can apply online by visiting the official website.
  • The prospectus is available from select branches SBI Bank and HDFC Banks till 31.07.2013.
  • The prospectus can be purchased from Sikkim Manipal University, Admissions office by writing to the following address by enclosing a request along with a demand draft for Rs. 600/- drawn in the name of Sikkim Manipal University payable at Gangtok.
For more details and information on how to apply, please visit their official website.
Selection procedure for SMIT, Rangpo
  • For MBBS Program: The selections of candidates are done based on NEET-UG 2013 entrance examination.
  • For BMLT, MPT and M.Sc (Medical) Programs: The selections of candidates are done based on merit basis in qualifying examinations.
For more details and information on selection procedure, please visit their official website.
Important Dates
  • Last date for submission of online application forms with late fee for Rs.1000/-: Thursday, January 31, 2013.
  • Last submission date of application form for MPT program: Saturday, June 29, 2013.
  • Last submission date of application form for BMTL and M.Sc (Medical) program:Tuesday, July 30, 2013.
For more information on college and courses, please click SMIT, Rangpo

Goa University Invites Applications for Integrated MBA Program


Applications are invited by Goa University for admission to Integrated Master of Business Administration (MBA) program offered in Hospitality, Travel and Tourism at Department of Management Studies for the academic year 2013.
Eligibility Criteria for Goa University:
Candidates passed in 12th standard are eligible to apply.
How to Apply for Goa University:
  • Download the application form from the website: www.unigoa.ac.in and send the filled in form with the required DD.
  • Goa University IMBA prospectus and application form can be obtained from the Department of Management Studies, Goa University, Goa-403206 by sending a DD for Rs.500/- (Rupees Five Hundred Only) in favor of “Registrar, Goa University” payable at any bank in Panaji (Panjim) .
  • Application forms are also available for sale at State Bank of India, near Hotel Mandovi, Panjim.
For more details and information on how to apply, please visit their official website.
Selection procedure for Goa University:
The selections of candidates are done based on merit basis in qualifying examinations
Important Dates
Last date for the receipt of application form: Friday, May 24, 2013.
For more information on college and courses, please click Goa University

NIT Warangal Invites Applications for MBA Program


Applications are invited by National Institute of Technology (NIT), Warangal for admission to two year full-time Master of Business Administration (MBA) program offered at School of Management for the academic year 2013.
Eligibility Criteria for NIT, Warangal:
  • Applicant should be a citizen of India.
  • Candidates with first class bachelor’s degree in any branch of Engineering/Technology from a recognized university with at least 60% marks in aggregate (I to IV year) or 6.4 CGPA and with a valid CAT/MAT score are eligible to apply.
  • Candidates awaiting the Results of the final semester/year may also apply.
For more details and information on eligibility criteria, please visit their official website.
How to Apply for NIT, Warangal:
  • Application form and other details can be downloaded from the institute website: www.nitw.ac.in.
  • Application fee is Rs. 1000/- (Rs. 500/- for SC/ST candidates).
  • Applications are to be submitted along with photocopies of necessary certificates and demand draft for Rs. 1000/- (Rs. 500/- for SC/ST candidates) drawn in favor of Director, NIT Warangal, payable at S.B.H, NIT Warangal Branch (Code No. 20149) or any other Nationalized Bank payable at Warangal.
For more details and information on how to apply, please visit their official website.
Selection procedure for NIT, Warangal:
Selections of candidates are done based on valid CAT/MAT score followed by group discussion and personal interview conducted by the university.
Important Dates
Last date for receipt of filled in application form: Monday, March 04, 2013.
For more details and information on important dates, please visit their official website.
For more information on college and courses, please click NIT, Warangal

Indian School of Mines Invites Applications for M.Sc Tech. Programs


Applications are invited by Indian School of Mines (ISM), Dhanbad for admission to three year M.Sc Tech. in Applied Geology, Applied Geophysics and five year Integrated M.Sc Tech. programs in Applied Geology, Applied Geophysics, Mathematics and Computing for the academic year 2013-14.
Eligibility Criteria for ISM, Dhanbad:
  • For 3-year M.Sc Tech. in Applied Geology Program:
    • Candidates holding B.Sc degree (3-year) with Geology as honours/major/main/equivalent subject and any two subsidiary subjects from Mathematics, Physics and Chemistry are eligible to apply.
  • For 3-year M.Sc Tech. in Applied Geophysics Program:
    • Candidates holding B.Sc degree (3-year) with Physics as honours/major/main/equivalent subject, Mathematics as a subsidiary subject and another subsidiary subject from Chemistry, Geology, Geography, Electronics, Statistics and Computer Science are eligible to apply.
For more details and information on eligibility criteria, please visit their official website.
How to Apply for ISM, Dhanbad:
  • Candidates can download the information bulletin from I.S.M. website:www.ismdhanbad.ac.in.
  • The application form should be filled up online through I.S.M. website. After filling the details on the application form, applicants are required to submit the application online and take a printout of the system generated application form.
  • The candidates are required to send the printout of the system generated application form, payment receipt (Rs.750/- for SC/ST/PD candidates only and Rs.1,500/- for all other categories of candidates), photocopies of all certificates and mark sheets to the office of the Deputy Registrar (Exam & Academic), Indian School of Mines, Dhanbad-826004, Jharkhand on or before April 08, 2013.
  • The envelope containing the print out of system generated application form and all other relevant documents should be super scribed as “Admission to M.Sc. /M.Sc. Tech. 2013”.
For more details and information on how to apply, please visit their official website.
Selection procedure for ISM, Dhanbad:
  • For 3-year M.Sc Tech Program: The selections of candidates are done based on IIT Joint Entrance Examination.
  • For 5-year M.Sc Tech Program: The selections of candidates are done based on All India Entrance Examination conducted by I.S.M.
Important Dates
  • Closing date of online application: Sunday, March 31, 2013.
  • Last date for submission of application form along with documents at the office: Monday, April 08, 2013.
  • Date of entrance examination: Sunday, May 12, 2013.
For more information on college and courses, please click ISM, Dhanbad

Sikkim Manipal Institute of Technology Invites Applications for BBA Program


Applications are invited by Sikkim Manipal Institute of Technology (SMIT), Rangpo for admission to Bachelor of Business Administration (BBA) program for the commencing session 2013.
Eligibility Criteria for SMIT, Rangpo:
  • Candidates must have passed 10+2 or equivalent examination in any stream from recognized board/university with 50% marks in aggregate for general (45% for ST, SC & OBC) with adequate proficiency in English.
  • Candidates through central counseling conducted by Manipal University, Manipal (Karnataka) are also eligible to apply.
How to Apply for SMIT, Rangpo:
  • Candidates can apply online by visiting the official website.
  • The prospectus is available from select branches SBI Bank and HDFC Banks till 31.07.2013.
  • The prospectus can be purchased from Sikkim Manipal University, Admissions office by writing to the following address by enclosing a request along with a demand draft for Rs. 600/- drawn in the name of Sikkim Manipal University payable at Gangtok.
For more details and information on how to apply, please visit their official website.
Selection procedure for SMIT, Rangpo:
The selections of candidates are done based on merit scores obtained in qualifying examinations.
Important Dates
Last date of submission of application forms: Wednesday, July 10, 2013.
For more information on college and courses, please click SMIT, Rangpo

Banasthali University, Jaipur Invites Applications for B.Tech/M.Tech Programs


Applications are invited by Banasthali University, Jaipur for admission to four year Bachelor of Technology (B.Tech) in Computer Science and Engineering, Electronics and Instrumentation, Electrical and Electronics, Information Technology, Biotechnology, Chemical Engineering and 2 year Master of Technology (M.Tech) in Computer Science and IT, VLSI Design and Remote Sensing programs for the commencing session of 2013-14. Admission to Banasthali Vidyapith is open to women candidates only.
Eligibility Criteria for Banasthali University, Jaipur:
  • For B.Tech:Candidates holding 10+2 with 60% in Physics, Chemistry and Maths are eligible to apply.
  • For M.Tech:
    • For M.Tech (Comp. Sc/IT): Candidates holding a degree in B.E/B.Tech (C.S & Engg.)/M.Sc (C.S)/MCA/M.Sc. Maths (TCS) with a minimum of 55% aggregate marks are eligible to apply.
    • For M.Tech (VLSI Design): Candidates holding a degree in B.E/B.Tech (C.S/ Elec.)/M.Sc (C.S)/MCA/M.Sc. (Elec.) with a minimum of 55% aggregate marks are eligible to apply.
    • For M.Tech (Remote Sensing): B.E/B.Tech/B.Arch or master’s degree in Remote Sensing or any discipline of Science/Earth Science is eligible to apply.
For more details and information on eligibility criteria, please visit their official website.
How to Apply for Banasthali University, Jaipur:
  • Candidates will have to send a DD for Rs. 800/- in favour of "Banasthali Vidyapith" payable at Banasthali/Jaipur to: Secretary - Banasthali Vidyapith, P.O. Banasthali Vidyapith - 304022 (Rajasthan).
  • Prospectus and form can also be obtained in person upon payment of Rs. 700/- in cash.
  • Online submissionof application is also possible on the Banasthali Vidyapith's website.
For more details and information on application procedure, please visit theirofficial website.
Selection procedure for Banasthali University, Jaipur:
Selection of the candidates for B.Tech/M.Tech in Comp. Sc/IT and VLSI Design programs is done on the basis of an aptitude test conducted by the University.
Important Dates:
  • Last date of submission of admission form:
    • Without late fee: Tuesday, April 30, 2013.
    • With late fee of Rs.900/-: Wednesday, May 15, 2013.
  • Date of B.Tech aptitude test: Saturday, June 01, 2013.
  • Date of M.Tech aptitude test: Sunday, June 02, 2013.
For more information on college and courses, please click Banasthali University, Jaipur

Friday, January 11, 2013

Simple Breath Test Finds TB, Lung Infections


Bacteria that cause lung infections like tuberculosis (TB) release volatile organic compounds that end up in exhaled breath. Now scientists have identified the unique "chemical fingerprints" given off by different bacteria in the lungs in a way that potentially allows for the diagnosis of such lung infections via a quick and simple breath test.

The researchers, from the University of Vermont in the US, write about their findings in the 10 January issue of the online Journal of Breath Research.

The study was conducted on mice, but if it can be repeated in humans, then the hope is that a simple breath test could reduce the time taken to diagnose lung infections from days and weeks to minutes.

Another advantage of the breath-test method over the current alternative is that it is easy to administer and non-invasive.

Current Diagnosis Of Lung Infection Is Lengthy and Laborious

Currently, correct diagnosis of bacterial lung infection requires taking a sample, growing a colony of bacteria from it in a lab, then doing biochemical tests to find out the class of bacteria and which antibiotics it is resistant to.

Co-author Jane Hill says in a press statement:

"This whole process can take days for some of the common bacteria and even weeks for the causative agent for tuberculosis. Breath analysis would reduce the time-to-diagnosis to just minutes."

The Study

For their study, Hill and colleagues infected mice with two bacteria that are common in acute and chronic lung infections, Pseudomonas aeruginosa and Staphylococcus aureus, and then tested their breath after 24 hours. They also tested the breath of a second group of uninfected mice for comparison.

The method they used to test for volatile organic compounds is called secondary electrospray ionization mass spectrometry (SESI-MS). The technique can find minute traces of such compounds, down to one part per trillion.

When they analyzed the results, the researchers found a statistically significant difference in the chemical breath profiles of the infected and uninfected mice.

The team was also able to identify the two species of bacteria, to a level that was statistically significant. The researchers could even distinguish between the two strains of P. aeruginosathey used.

Strong Evidence

Hill says the study provides strong evidence that it is possible to use SESI-MS breathprints to distinguish among different bacterial infections in mice, and it is very likely the same method would be able to identify bacterial, viral and fungal infections of the lung.

She and her colleagues propose that as in mice, when bacteria infect the lungs of humans, they produce unique volatile organic compounds that are not present in exhaled breath of uninfected people, due to their different metabolism.

The team is now collaborating with others to test their new approach on samples taken from human patients. Breath tests are already being investigated to diagnose cancerasthma,diabetes and other diseases.

In October 2011, scientists reported developing a breath test based on a sensor array that can diagnose multiple sclerosis (MS), the most common neurological disease in young adults

Written by Catharine Paddock PhD 
Source:MNT